United States
Germany
Japan
United Kingdom
China
CREB3L1 (NM_052854) Human Tagged ORF Clone Lentiviral Particle
CAT＃: RC204968L3V
- LentiORF®
-
Lenti ORF particles, CREB3L1 (Myc-DDK tagged) - Human cAMP responsive element binding protein 3-like 1 (CREB3L1), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 8,930.00
货期*
详询
规格
Product images
经常一起买 (3)
Specifications
| Product Data | |
| Product Name | CREB3L1 (NM_052854) Human Tagged ORF Clone Lentiviral Particle |
| Synonyms | OASIS; OI16 |
| Vector | pLenti-C-Myc-DDK-P2A-Puro |
| ACCN | NM_052854 |
| ORF Size | 1557 bp |
| Sequence Data |
The ORF insert of this clone is exactly the same as(RC204968).
|
| OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| Reference Data | |
| RefSeq | NM_052854.2 |
| RefSeq Size | 2741 bp |
| RefSeq ORF | 1560 bp |
| Locus ID | 90993 |
| Domains | BRLZ |
| Protein Families | Transcription Factors |
| Protein Pathways | Huntington's disease, Melanogenesis, Prostate cancer |
| MW | 57 kDa |
| Gene Summary | The protein encoded by this gene is normally found in the membrane of the endoplasmic reticulum (ER). However, upon stress to the ER, the encoded protein is cleaved and the released cytoplasmic transcription factor domain translocates to the nucleus. There it activates the transcription of target genes by binding to box-B elements. [provided by RefSeq, Jun 2013] |
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
You may also need
其它CREB3L1产品
Customer
Reviews
Loading...
